Interdisciplinary Working Group for Movement Disorders
Meta-Analysis of Neutralizing Antibody Conversion with OnabotulinumtoxinA (BOTOX®) Across Multiple Indications: Naumann M et al.
Movement Disorders
Vol. 25, No. 13, 2010, pp. 2211–2218
©2010 Movement Disorder Society
Authors:
Markus Naumann, MD, 1*
Alastair Carruthers, MD, 2
Jean Carruthers, MD, 3
Sheena K. Aurora, MD, 4
Ross Zafonte, DO, 5
Susan Abu-Shakra, MD, 6
Terry Boodhoo, MS, 6
Mary Ann Miller-Messana, RN, 6
George Demos, MD, 6
Lynn James, MPH, 6
Frederick Beddingfield, MD, PhD, 6,7
Amanda VanDenburgh, PhD, 6
Mary Ann Chapman, PhD, 8
and Mitchell F. Brin, MD 6,9
Author Details:
1 Department of Neurology, Klinikum Augsburg Neurologische Klinik, Augsburg, Germany
2 Department of Dermatology and Skin Science, University of British Columbia, Canada
3 Department of Ophthalmology and Visual Sciences, University of British Columbia, Canada
4 Swedish Pain and Headache Center, Seattle, Washington, USA
5 Harvard Medical School, Spaulding Rehabilitation Hospital Massachusetts General Hospital, Boston, Massachusetts, USA
6 Allergan, Inc., Irvine, California, USA
7 Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, USA
8 Visage Communications, Mead, Washington, USA
9 Department of Neurology, University of California, Irvine, California, USA
Unsere Zertifizierer
